Business Wire

The Pink Ribbon Turns 25: The Estée Lauder Companies’ Breast Cancer Campaign Reaches 25 Year Milestone

Jaa

The Estée Lauder Companies honors the 25th Anniversary of The Breast Cancer Campaign (formerly known as The Breast Cancer Awareness Campaign) and the co-creation of the iconic pink ribbon by its visionary founder, the late Evelyn H. Lauder.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005489/en/

The 2017 Estée Lauder Companies' Breast Cancer Campaign ad visual (Graphic: Business Wire)

The 2017 Estée Lauder Companies' Breast Cancer Campaign ad visual (Graphic: Business Wire)

25 years ago there was no pink ribbon. Women around the world were dying from breast cancer and there was very little discussion about it. Mrs. Lauder saw an urgent need to bring breast cancer to the forefront and put a spotlight on this world health issue. In 1992, she became a pioneer for the breast cancer movement, co-creating the pink ribbon and launching The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign). A year later, she founded the Breast Cancer Research Foundation® (BCRF), a non-profit organization, to generate funding solely dedicated to breast cancer research. Today, the pink ribbon is the ubiquitous symbol of breast health and The Campaign is a global leading voice for breast cancer, igniting a worldwide movement that has funded innovative research and awareness, and inspired meaningful action.

To mark the 25th Anniversary, The Estée Lauder Companies has a new mission: to create a breast cancer-free world. A bold, thought-provoking visual of a tattered pink ribbon is being introduced, showing the wear and tear of 25 years of hard work, dedication and impact trying to cure this disease. It also represents the hope that in 25 years, there will be no need for a pink ribbon; breast cancer will be committed to the history books. The Campaign no longer carries the word “Awareness” as breast cancer now has the global spotlight it deserves, moving into the future with a new rally – it’s time to end breast cancer.

The Campaign is now active in more than 70 countries around the world, partnering with more than 60 regional organizations to address areas of most critical need. The Campaign has raised more than $70 million to support global research, education and medical services, funding 225 medical research grants through BCRF ($56 million from total funds raised). To date:

  • Breast cancer mortality rates have decreased by 38% since the late 1980s.1
  • Five-year survival rates are better than 90% when breast cancer is found early2
  • Treatments are being customized to a person’s type of breast cancer, as breast cancer was revealed to be not one disease, but several different types
  • Surgery is not as invasive, and most women can have a lumpectomy and not a full breast removal (mastectomy)

William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc., continues to honor the legacy of his late mother and proudly champions The Campaign’s work worldwide stating, “Supporting the development of critical research, driving awareness, and helping to eliminate the cultural barriers that can prevent the identification and treatment of breast cancer has been our core Company focus since my mother Evelyn H. Lauder founded The Breast Cancer Campaign 25 years ago. I am continuously humbled and energized by the passion and care exhibited by our employees and the tireless dedication of our partners—whose work is getting us closer to a global cure each and every day. As a Company, our commitment has not and will not waver.”

The Campaign unites partners and influencers worldwide, demonstrating the power of taking action together and inspiring others to make a difference. “Throughout my travels as Global Ambassador for The Estée Lauder Companies’ Breast Cancer Campaign, I’ve seen the hope that advancing breast cancer research is bringing,” said Elizabeth Hurley, Global Ambassador for The Breast Cancer Campaign. “I’ve seen first-hand the strength of those fighting breast cancer and the strength of friends and family who are supporting them in their fight, and I truly believe that together we can help turn the corner and bring breast cancer to an end.”

The Estée Lauder Companies is launching global efforts to support The Campaign:

  • Largest-ever one-year commitment of $8 million in financial contributions
  • A social fundraising effort, in which The Estée Lauder Companies will donate $25 to fund a half-hour of breast cancer research through BCRF for every unique post on Instagram or Twitter with both #PinkRibbon25 and #ELCdonates between September 15, 2017 and October 31, 2017, with the goal of funding a maximum of 500 research hours
  • Illumination of buildings, monuments and landmarks worldwide in glowing pink lights to raise awareness of breast health – including the Empire State Building, New York City and the Eiffel Tower, Paris
  • Release of a documentary short film, “Unraveling the Pink Ribbon: Creating a Breast Cancer-Free World,” directed by Sophy Holland, honoring Mrs. Lauder and highlighting progress made
  • Distribution of informational brochures and pink ribbons at The Estée Lauder Companies’ beauty brand counters worldwide

“The Estée Lauder Companies has long been committed to making an impact on communities around the world, and our efforts through The Breast Cancer Campaign are a reflection of that purpose,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc. “The awareness we’ve brought to the movement brings us great pride, and fuels the next – and what we hope to be the last - stage of The Campaign: ending breast cancer.”

The following brands of The Estée Lauder Companies will support The Campaign's mission: Aveda, Bobbi Brown, Bumble and bumble, Clinique, Darphin, DKNY, Donna Karan, Estée Lauder, Jo Malone London, La Mer, Lab Series, Origins, Prescriptives, Smashbox, Tom Ford Beauty and Tory Burch. Each will contribute by selling Pink Ribbon Products or making donations to BCRF and/or other charitable organizations around the world. This assortment differs by country and organization.

To support the 25th Anniversary of The Estée Lauder Companies’ Breast Cancer Campaign, visit bcacampaign.com, follow on social media @bcacampaign and use #PinkRibbon25.

ABOUT THE ESTÉE LAUDER COMPANIES INC.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA and Too Faced.

1. Source: American Cancer Society Cancer Facts and Figures 2017 (https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html)

2. Source: American Cancer Society Understanding Breast Cancer Survival Rates (https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html)

Contact information

The Estée Lauder Companies
Bari Seiden-Young, 212-572-4475
bseiden@estee.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54Tiedote

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Tradeshift Announces Q3 2018 Results19.10.2018 14:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00Tiedote

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme